Hepion Pharmaceuticals, Inc.

OTC: HEPA · Healthcare · Biotechnology

PublicHQ Edison, NJCIK 0001583771Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

25D

FH 26DQ 18GM —SS 42

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.3M

Employees

Market cap

$978.1k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02023

Net income-$8.3M-$8.3M2025

Operating income-$4.2M-$4.2M2025

Total assets$3.1M$3.1M2025

Liabilities$402.4k$402.4k2025

Equity$2.7M$2.7M2025

Revenue trend

FY2021 – FY2023 · USD

FY21

FY22

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Hepion Pharmaceuticals, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

EVIO, Inc.——AIM ImmunoTech Inc.36D Avenue Therapeutics, Inc.25D Stella Diagnostics Inc.——

Key facts

CEOGary S. Stetz

SectorHealthcare

IndustryBiotechnology

HeadquartersEdison, NJ

ExchangeOTC: HEPA

Employees22

IPO date2014-02-10

Latest filings

8-K2026-07-02 8-K2026-06-17 10-Q2026-05-14 DEF 14A2026-04-28 8-K2026-04-22 8-K2026-04-14 8-K2026-03-18 10-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.